- Home
- ENTA vs SEVN Comparison
ENTA vs SEVN Comparison
Compare ENTA & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- SEVN
- Stock Information
- Founded
- ENTA 1995
- SEVN 1986
- Country
- ENTA United States
- SEVN United States
- Employees
- ENTA N/A
- SEVN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- SEVN Real Estate Investment Trusts
- Sector
- ENTA Health Care
- SEVN Real Estate
- Exchange
- ENTA Nasdaq
- SEVN Nasdaq
- Market Cap
- ENTA 160.3M
- SEVN 179.3M
- IPO Year
- ENTA 2013
- SEVN N/A
- Fundamental
- Price
- ENTA $7.89
- SEVN $12.85
- Analyst Decision
- ENTA Buy
- SEVN Strong Buy
- Analyst Count
- ENTA 4
- SEVN 3
- Target Price
- ENTA $18.00
- SEVN $14.75
- AVG Volume (30 Days)
- ENTA 181.3K
- SEVN 47.8K
- Earning Date
- ENTA 08-04-2025
- SEVN 07-28-2025
- Dividend Yield
- ENTA N/A
- SEVN 10.89%
- EPS Growth
- ENTA N/A
- SEVN N/A
- EPS
- ENTA N/A
- SEVN 1.15
- Revenue
- ENTA $64,462,999.00
- SEVN $30,074,000.00
- Revenue This Year
- ENTA N/A
- SEVN $7.45
- Revenue Next Year
- ENTA $0.48
- SEVN $1.12
- P/E Ratio
- ENTA N/A
- SEVN $11.18
- Revenue Growth
- ENTA N/A
- SEVN N/A
- 52 Week Low
- ENTA $4.09
- SEVN $10.18
- 52 Week High
- ENTA $17.24
- SEVN $14.66
- Technical
- Relative Strength Index (RSI)
- ENTA 67.33
- SEVN 73.43
- Support Level
- ENTA $6.95
- SEVN $11.78
- Resistance Level
- ENTA $8.23
- SEVN $12.06
- Average True Range (ATR)
- ENTA 0.40
- SEVN 0.29
- MACD
- ENTA 0.00
- SEVN 0.10
- Stochastic Oscillator
- ENTA 75.11
- SEVN 100.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.